Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Birmingham, Alabama 35233


Purpose:

The purpose of this study is to determine whether erlotinib will be effective in controlling cancer that has returned after treatment with radiation. This study will also determine what effects, good and/or bad, this drug has.


Criteria:

Inclusion Criteria: 1. Pathologically confirmed diagnosis of recurrent or second primary squamous cell carcinoma 2. Recurrence or second primary of the oral cavity, oropharynx, hypopharynx, or larynx. Recurrent neck metastasis with unknown primary is allowed 3. Prior radiation therapy for head and neck cancer 4. Disease must be considered surgically resectable or candidate for curative reirradiation 5. Adequate diagnostic workup 6. Zubrod Performance Status 0-2 7. Life expectancy 12 weeks 8. Age 19, 9. Adequate laboratory data. Exclusion Criteria: 1. Prior invasive cancers other than head and neck cancer unless disease free for a minimum of 3 years. (Prior non-melanomatous skin cancer and previous carcinoma in situ are permissible) 2. Patients who are pregnant or lactating 3. Psychological condition that renders the patient unable to understand the informed consent 4. Any situation or condition that will interfere with adherence to study activities.


NCT ID:

NCT00570232


Primary Contact:

Principal Investigator
Eben Rosenthal, MD
University of Alabama at Birmingham


Backup Contact:

N/A


Location Contact:

Birmingham, Alabama 35233
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.